By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Kamada Ltd. 

Kibbutz Beit Kama M.P.

Negev    85325  Israel
Phone: 07-991-2082 Fax: 07-991-2083


SEARCH JOBS


Industry
Biotechnology

Segment
Pharmaceuticals





Company News
Kamada Ltd. (KMDA) Announces Collaboration Agreement With Yissum Ltd. For Development Of A Recombinant Human Alpha 1 Antitrypsin 11/15/2016 9:23:48 AM
Kedrion And Kamada Ltd. (KMDA) Announce FDA Acceptance Of BLA Submission For Human Rabies Immunoglobulin As A Post-Exposure Treatment 11/7/2016 9:09:44 AM
Kamada Ltd. (KMDA) To Host Third Quarter Financial Results Conference Call On November 10, 2016 At 8:30 Am Eastern Time 11/3/2016 9:04:41 AM
Kamada Ltd. (KMDA) Announces Plan For Phase II/III Clinical Trial With Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease 11/2/2016 7:27:22 AM
Kamada Ltd. (KMDA) Announces Extension Of GLASSIA┬« Supply And Distribution Agreement With Shire (SHPG) With Minimum $237 Million Of Revenue For The Years 2017 To 2020 10/6/2016 7:12:18 AM
Kamada Ltd. (KMDA) To Present A Corporate Overview At The Rodman & Renshaw 18th Annual Investment Conference 9/9/2016 7:34:27 AM
Kamada Ltd. (KMDA) And Kedrion Seek FDA Approval Of Human Rabies Immunoglobulin As A Post-Exposure Treatment 9/1/2016 11:13:01 AM
Kamada Ltd. (KMDA) Meets Primary Endpoint Of U.S. Phase II Study Of Inhaled Alpha-1 Antitrypsin For The Treatment Of Alpha-1 Antitrypsin Deficiency 8/30/2016 8:04:34 AM
Kamada Ltd. (KMDA) Reports Financial Results For The Second Quarter And First Six Months Of 2016 8/2/2016 8:32:56 AM
Shire (SHPG) And Kamada Ltd. (KMDA) Announce FDA Approval Of Expanded Label For Self-Infusion Of GLASSIA For The Treatment Of Emphysema Due To Severe AAT Deficiency 6/15/2016 11:28:02 AM
12345678910...
//-->